bevacizumab - CISMeF

Preferred Label : bevacizumab;

UMLS semantic type : T121 - Pharmacologic Substance; T129 - Immunologic Factor;

Is substance : O;

Origin ID

M0443627;

UMLS CUI

C0796392;

Currated CISMeF NLP mapping
- Bevacizumab [Substance BNPC]
- Bevacizumab [SMS substance]
- Bevacizumab [ICD-11 Extension code]
- Bevacizumab [Anticorps monoclonal]
- Bevacizumab [NCIt concept]
- Bevacizumab (substance) [SNOMED CT concept]
- bevacizumab [International Nonproprietary Name]
MeSH narrower concept(s)
- Bevacizumab-awwb [MeSH concept]
- Mvasi [MeSH concept]
- avastin [MeSH concept]
Related record
- Bevacizumab [MeSH Descriptor]
See also inter- (CISMeF)
- Product containing bevacizumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Anti-VEGF Monoclonal Antibody [NCIt concept]
- Bevacizumab [NCIt concept]
- Bevacizumab (substance) [SNOMED CT concept]
- Product containing bevacizumab (medicinal product) [SNOMED CT concept]
- bevacizumab [ATC Code]
- bevacizumab [International Nonproprietary Name]
- bevacizumab [ATC Code]
Validated automatic mappings to BTNT
- bevacizumab [ATC Code]
Validated automatic mappings to NTBT
- Anti-VEGF Monoclonal Antibody [NCIt concept]